US pharma giant Pfizer (NYSE: PFE) says that it will submit a New Drug Application with the US Food and Drug Administration for palbociclib, combined with letrozole, as first-line systemic treatment of post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer, early in the third quarter of this year.
This decision was based on discussions with the FDA regarding the final results of PALOMA-1, a randomized, Phase II trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients. As yet, palbociclib is not approved for any indication in any market.
Last year, palbociclib received Breakthrough Therapy designation from the FDA for the first-line systemic treatment of women with advanced or metastatic ER+, HER2- breast cancer (The Pharma Letter April 11, 2013). This designation was based on interim data from the PALOMA-1 trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze